Literature DB >> 15285027

Prevalence of subclinical hepatic encephalopathy in cirrhotic patients in China.

Yu-Yuan Li1, Yu-Qiang Nie, Wei-Hong Sha, Zheng Zeng, Fu-Ying Yang, Li Ping, Lin Jia.   

Abstract

AIM: Subclinical hepatic encephalopathy (SHE) is a common complication of liver diseases. The aim of this study was to find out the normal value of psychometric test and to investigate the prevalence of SHE in Chinese patients with stabilized hepatic cirrhosis.
METHODS: Four hundred and nine consecutive cirrhotic patients without overt clinical encephalopathy were screened for SHE by using number connection test part A (NCT-A) and symbol digit test (SDT). SHE was defined as presence of at least one abnormal psychometric test. The age-corrected normal values were defined as the mean+/-2 times standard deviation (2SD), and developed in 356 healthy persons as normal controls. Four hundred and sixteen patients with chronic viral hepatitis were tested as negative controls to assess the diagnostic validity of this test battery.
RESULTS: There was no significant difference in NCT scores and SDT quotients between healthy controls and chronic hepatitis group (P>0.05). In all age subgroups, the NCT and SDT measurements of cirrhotic patients differed significantly from those of the controls (P<0.05). When mean+/-2SD of SDT and NCT measurements from healthy control group was set as the normal range, 119 cirrhotic patients (29.1%) were found to have abnormal NCT-A and SDT tests, 53 (13.0%) were abnormal only in SDT and 36 (8.8%) only in NCT-A. Taken together, SHE was diagnosed in 208 (50.9%) cirrhotic patients by this test battery. The prevalence of SHE increased from 39.9% and 55.2% in Child-Pugh's grade A and B groups to 71.8% in Child-Pugh's grade C group (P<0.05). After the adjustment of age and residential areas required from the tests, no correlation was found in the rate of SHE and causes of cirrhosis, education level and smoking habit.
CONCLUSION: Psychometric tests are simple and reliable indicators for screening SHE among Chinese cirrhotic patients. By using a NCT and SDT battery, SHE could be found in 50.9% of cirrhotic patients without overt clinical encephalopathy. The prevalence of SHE is significantly correlated with the severity of liver functions.

Entities:  

Mesh:

Year:  2004        PMID: 15285027      PMCID: PMC4576296          DOI: 10.3748/wjg.v10.i16.2397

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  26 in total

1.  Efficacy of lactulose in cirrhotic patients with subclinical hepatic encephalopathy.

Authors:  R K Dhiman; M S Sawhney; Y K Chawla; G Das; S Ram; J B Dilawari
Journal:  Dig Dis Sci       Date:  2000-08       Impact factor: 3.199

2.  Prevalence and natural history of subclinical hepatic encephalopathy in cirrhosis.

Authors:  A Das; R K Dhiman; V A Saraswat; M Verma; S R Naik
Journal:  J Gastroenterol Hepatol       Date:  2001-05       Impact factor: 4.029

3.  Somatosensory evoked potentials and number connection test in the detection of subclinical hepatic encephalopathy.

Authors:  C L Yen; Y F Liaw
Journal:  Hepatogastroenterology       Date:  1990-06

4.  Neurophysiological evidence of cognitive impairment in patients without hepatic encephalopathy after transjugular intrahepatic portosystemic shunts.

Authors:  Ludwig Kramer; Edith Bauer; Alexandra Gendo; Georg Funk; Christian Madl; Johann Pidlich; Alfred Gangl
Journal:  Am J Gastroenterol       Date:  2002-01       Impact factor: 10.864

5.  NMR spectroscopy in portal-systemic encephalopathy: are we there yet?

Authors:  S Schenker; R Butterworth
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

6.  High prevalence of sleep disturbance in cirrhosis.

Authors:  J Córdoba; J Cabrera; L Lataif; P Penev; P Zee; A T Blei
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

7.  Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy.

Authors:  M Romero-Gómez; F Boza; M S García-Valdecasas; E García; J Aguilar-Reina
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

8.  Clinical features and survivial of cirrhotic patients with subclinical cognitive alterations detected by the number connection test and computerized psychometric tests.

Authors:  P Amodio; F Del Piccolo; P Marchetti; P Angeli; R Iemmolo; L Caregaro; C Merkel; G Gerunda; A Gatta
Journal:  Hepatology       Date:  1999-06       Impact factor: 17.425

9.  Hepatic encephalopathy--definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.

Authors:  Peter Ferenci; Alan Lockwood; Kevin Mullen; Ralph Tarter; Karin Weissenborn; Andres T Blei
Journal:  Hepatology       Date:  2002-03       Impact factor: 17.425

10.  Latent portasystemic encephalopathy. I. Nature of cerebral functional defects and their effect on fitness to drive.

Authors:  H Schomerus; W Hamster; H Blunck; U Reinhard; K Mayer; W Dölle
Journal:  Dig Dis Sci       Date:  1981-07       Impact factor: 3.199

View more
  18 in total

1.  Critical flicker frequency and continuous reaction times for the diagnosis of minimal hepatic encephalopathy: a comparative study of 154 patients with liver disease.

Authors:  Mette Munk Lauridsen; Peter Jepsen; Hendrik Vilstrup
Journal:  Metab Brain Dis       Date:  2011-04-12       Impact factor: 3.584

2.  Multidimensional assessment of neuro-psychiatric symptoms in patients with low-grade hepatic encephalopathy: a clinical rating scale.

Authors:  Sergei Mechtcheriakov; Ivo-W Graziadei; André Kugener; Julia Wiedemann; Chantal Galbavy; Hartmann Hinterhuber; Josef Marksteiner; Wolfgang Vogel
Journal:  World J Gastroenterol       Date:  2005-10-07       Impact factor: 5.742

3.  Abnormal baseline brain activity in patients with HBV-related cirrhosis without overt hepatic encephalopathy revealed by resting-state functional MRI.

Authors:  Xiao-Fei Lv; Min Ye; Lu-Jun Han; Xue-Lin Zhang; Pei-Qiang Cai; Gui-Hua Jiang; Ying-Wei Qiu; Shi-Jun Qiu; Yao-Pan Wu; Kai Liu; Zhen-Yin Liu; Pei-Hong Wu; Chuan-Miao Xie
Journal:  Metab Brain Dis       Date:  2013-07-09       Impact factor: 3.584

4.  Improvement of regional cerebral blood flow after oral intake of branched-chain amino acids in patients with cirrhosis.

Authors:  Mika Yamamoto; Motoh Iwasa; Kaname Matsumura; Yuri Nakagawa; Naoki Fujita; Yoshinao Kobayashi; Masahiko Kaito; Kan Takeda; Yukihiko Adachi
Journal:  World J Gastroenterol       Date:  2005-11-21       Impact factor: 5.742

5.  Minimal hepatic encephalopathy matters in daily life.

Authors:  Jasmohan S Bajaj
Journal:  World J Gastroenterol       Date:  2008-06-21       Impact factor: 5.742

6.  Assessment of health-related quality of life in Chinese patients with minimal hepatic encephalopathy.

Authors:  Zhi-Jun Bao; De-Kai Qiu; Xiong Ma; Zhu-Ping Fan; Gan-Sheng Zhang; Yi-Qin Huang; Xiao-Feng Yu; Min-De Zeng
Journal:  World J Gastroenterol       Date:  2007-06-07       Impact factor: 5.742

Review 7.  Medical comorbidity and alcohol dependence.

Authors:  Paolo Mannelli; Chi Un Pae
Journal:  Curr Psychiatry Rep       Date:  2007-06       Impact factor: 5.285

8.  Prevalence of minimal hepatic encephalopathy and quality of life evaluations in hospitalized cirrhotic patients in China.

Authors:  Ji-Yao Wang; Ning-Ping Zhang; Bao-Rong Chi; Yu-Qing Mi; Li-Na Meng; Ying-Di Liu; Jiang-Bin Wang; Hai-Xing Jiang; Jin-Hui Yang; Yun Xu; Xiao Li; Jian-Ming Xu; Guo Zhang; Xin-Min Zhou; Yu-Zheng Zhuge; De-An Tian; Jin Ye; Yu-Lan Liu
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

9.  A current review of the diagnostic and treatment strategies of hepatic encephalopathy.

Authors:  Z Poh; P E J Chang
Journal:  Int J Hepatol       Date:  2012-10-21

10.  The effect of infections on the mortality of cirrhotic patients with hepatic encephalopathy.

Authors:  T H Hung; C J Lay; C M Chang; J J Tsai; C C Tsai; C C Tsai
Journal:  Epidemiol Infect       Date:  2013-02-22       Impact factor: 4.434

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.